FSMAX | MEFZX | FSMAX / MEFZX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 13 years | 14 years | - |
Gain YTD | 21.432 | 15.051 | 142% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 40B | 5.2B | 769% |
Annual Yield % from dividends | 1.10 | 0.00 | - |
Returns for 1 year | 37.46 | 20.91 | 179% |
Returns for 3 years | 2.73 | -31.92 | -9% |
Returns for 5 years | 54.93 | -5.27 | -1,041% |
Returns for 10 years | 86.34 | 13.34 | 647% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
BRUGX | 17.51 | N/A | N/A |
MFS Blended Research Value Equity C | |||
CFDRX | 15.93 | -0.04 | -0.25% |
Columbia Select Mid Cap Value Adv | |||
SEMGX | 18.56 | -0.13 | -0.70% |
DWS Emerging Markets Equity S | |||
MINFX | 36.16 | -0.32 | -0.88% |
MFS International Intrinsic Value R2 | |||
FTDZX | 153.99 | -2.11 | -1.35% |
Franklin Biotechnology Discovery Adv |